Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986184 in Healthy Subjects and Ulcerative Colitis
NCT02864264Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of BMS-986184 in ulcerative colitis (UC), sponsored by Bristol Myers Squibb. Started Sep 2016; status: terminated.
02
Drugs
BMS-986184
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02864264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864264.